Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Interpublic Group Unit Acquires Double Helix - Quick Facts

RELATED NEWS
Trade IPG now with 

McCann Health, a part of Interpublic Group (IPG: Quote), Monday announced the acquisition of Double Helix, a provider of market research and services to the pharmaceutical and medical device industries. The financial terms of the deal were not disclosed.

Wayne Phillips, who founded Double Helix in 1995, will continue as its CEO and will report to John Cahill, CEO of McCann Health.

McCann Health said Double Helix rounds out its impressive suite of services. The company said Double Helix's focus on innovation and novel collaborations within its network makes McCann Health the most differentiated and endowed, full-service global healthcare communications company.

Double Helix's Market Research division specialises in primary market research for its healthcare clients. The division focuses on the strategic and tactical business needs clients face throughout a product's lifecycle, from pre-clinical to post-launch. Double Helix's Market Access Consulting division assists clients to optimise the life cycle position of products in markets.

With four offices in London, New York, Philadelphia, and Singapore, Double Helix, apart from specialising in the established markets of the US and Europe, also focuses on emerging markets. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients.

Register
To receive FREE breaking news email alerts for Interpublic Group Of Companies Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Here is a list of interesting stocks to watch on December 19. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Shares of OvaScience Inc. (OVAS) have had a strong run in 2014, rising over 370 percent year-to-date. And that's indeed a very impressive return delivered by the fertility treatment company, which suffered a setback last year when it had to suspend a U.S. trial of its flagship fertility treatment due to regulatory concerns raised by the FDA. Nike Inc., the world's largest athletic shoes and apparel maker, said Thursday after the markets closed that its second quarter profit rose 23% from last year, helped by higher revenue and improved gross margin. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.